Function of CDK12 in tumor initiation and progression and its clinical consequences;Úloha CDK12 v iniciaci a rozvoji nádorů a její klinické konsekvence

Klinicka Onkologie

Volumn 27, Issue 5, 2014, Pages 340-346

  Vrabel D ^a   Svoboda, M ^b,c   Navratil J ^b   Kohoutek, J ^a  

^a Odd lení Chemie a Toxikologie Vyzkumny Ustav Veterinarniho Iekarstvi V V I   (Czech Republic)

^b MASARYK MEMORIAL CANCER INSTITUTE   (Czech Republic)

^c Oddělení Epidemiologie a Genetiky Nádorů Masarykův Onkologický Ústav ^*  (Czech Republic)

Author keywords

Cyclin dependent kinase 12; DNA repair; Mutation; PARP inhibitor; Platin cytostatics

Indexed keywords

CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE 12; UNCLASSIFIED DRUG; ALKYLATING AGENT; ANTINEOPLASTIC AGENT; CDK12 PROTEIN, HUMAN; CISPLATIN;

ARTICLE; CANCER GROWTH; DISEASE ASSOCIATION; PROTEIN FUNCTION; CARCINOGENESIS; CHROMOSOMAL INSTABILITY; DNA DAMAGE; DNA REPAIR; FEMALE; GENETIC TRANSCRIPTION; GENETICS; HUMAN; MUTATION; NEOPLASMS; OVARIAN NEOPLASMS; PHYSIOLOGY;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, ALKYLATING; CARCINOGENESIS; CHROMOSOMAL INSTABILITY; CISPLATIN; CYCLIN-DEPENDENT KINASES; DNA DAMAGE; DNA REPAIR; FEMALE; HUMANS; MUTATION; NEOPLASMS; OVARIAN NEOPLASMS; TRANSCRIPTION, GENETIC;

EID: 84908363983     PISSN: 0862495X     EISSN: 18025307     Source Type: Journal    
DOI: 10.14735/amko2014340     Document Type: Article

References (51)

1. Albini A, Spom MB. The tumour microenvironment as a target for chemoprevention. Nat Rev Cancer 2007;7(2):139-147.
2. Hanahan D, Weinberg RA. Hallmarks of cancer, the next generation. Cell 2011;144(5):646-674. doi: 10.1016/j. cell-2011.02.013.
3. Swartz MA, lida N, Roberts EW et al. Tumor microenvironment complexity: emerging roles in cancer therapy. Cancer Res 2012;72(10):2473-2480. doi: 10.1158/0008-5472. CAN-12-0122.
4. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100(1):57-70.
5. Malumbres M, Harlow E, Hunt T et al. Cyclin-dependent kinases: a family portrait. Nat Cell Biol 2009;11(11):1275-1276. doi: 10.1038/ncbl 109-1275.
6. Buratowski S. Progression through the RNA polymerase II CTD cycle. Mol Cell 2009;36(4):541-546. doi: 10.1016/j. molcel.2009.10.019.
7. Kohoutek J, Blazek D. Cyclin K goes with Cdk12 and Cdkl 3. Cell Div 2012;7:12. doi: 10.1186/1747-1028-7-12.
8. Loyer P, Trembley JH, Katona R et al. Role of CDK/cyclin complexes in transcription and RNA splicing. Cell Signal 2005;17(9):1033-1051.
9. Satyanarayana A, Kaldis P. Mammalian cell-cycle regulation: several Cdks, numerous cyclins and diverse compensatory mechanisms. Oncogene 2009;28(33):2925-2939. doi: 10.1038/onc2009.170.
10. Bajrami I, Frankum JR, Konde A et al. Genome-wide profiling of genetic synthetic lethality identifies CDK12 as a novel determinant of PARP1/2 inhibitor sensitivity. Cancer Res 2014;74(1):287-297. doi: 10.1158/0008-5472. CAN-13-2541.
11. Blazek O, Kohoutek J, Bartholomeeusen K et al. The Cyclin K/Cdk12 complex maintains genomic stability via regulation of expression of DNA damage response genes. Genes Dev 2011;25(20):2158-2172.
12. Ott M, Geyer M, Zhou Q. The control of HIV transcription: keeping RNA polymerase II on track. Cell Host Microbe 2011;10(5):426-435. doi: 10.1016/j.chom.2011.11.002.
13. Wang S, Fischer PM. Cyclin-dependent kinase 9: a key transcriptional regulator and potential drug target in oncology, virology and cardiology. Trends Pharmacol Sci 2008;29(6):302-313. doi: 10.1016/j.tips2008.03.003.
14. Zhou Q, Yik JH. The Yin and Yang of P-TEFb regulation: implications for human immunodeficiency virus gene expression and global control of cell growth and differentiation. Microbiol Mol Biol Rev 2006;70(3):646-659.
15. Barboric M, Nissen RM, Kanazawa S et al. NF-kappaB binds P-TEFb to stimulate transcriptional elongation by RNA polymerase II. Mol Cell 2001;8(2):327-337.
16. Kanazawa S, Soucek L, Evan G et al. c-Myc recruits P-TEFb for transcription, cellular proliferation and apoptosis. Oncogene 2003;22(36):5707-5711.
17. Wittmann BM, Fujinaga K, Deng H et al. The breast cell growth inhibitor, estrogen down regulated gene 1, modulates a novel functional interaction between estrogen receptor alpha and transcriptional elongation factor cyclin T1. Oncogene 2005;24(36):5576-5588.
18. Zhu R, Lu X, Pradhan M et al. A kinase-independent activity of Cdk9 modulates glucocorticoid receptor-mediated gene induction. Biochemistry 2014;53(11):1753-1767. doi: 10.1021/bi5000178.
19. Bartkowiak B, Liu P, Phatnani HP et al. CDK12 is a transcription elongation-associated CTD kinase, the metazoan ortholog of yeast Ctkl. Genes Dev 2010;24(20):2303-2316. doi: 10.1101/gad.1968210.
20. Ko TK, Kelly E, Pines J. CrkRS: a novel conserved Cdc2-related protein kinase that colocalises with SC35 speckles. J Cell Sci 2001;114(14):2591-2603.
21. loms E, Martens-de Kemp SR, Lord G et al. CRK7 modifies the MAPK pathway and influences the response to endocrine therapy. Carcinogenesis 2009;30(10):1696-1701. doi: 10.1093/carcin/bgp187.
22. Hertel KJ, Graveley BR. RS domains contact the pre-mRNA throughout spliceosome assembly. Trends Biochem Sci 2005;30(3):115-118.
23. Long JC Caceres JF. The SR protein family of splicing factors: master regulators of gene expression. Biochem J 2009;417(1):15-27. doi: 10.1042/BJ20081501.
24. Valcarcel J, Green MR. The SR protein family: pleiotropic functions in pre-mRNA splicing. Trends Biochem Sci 1996;21(8):296-301.
25. Zarrinpar A, Bhattacharyya RP, Lim WA. The structure and function of proline recognition domains. Sci STKE 2003;2003(179):RE8.
26. Ball U, Kuhne R, Schneider-Mergener J et al. Recognition of proline-rich motifs by protein-protein-interaction domains. Angew Chem Int Ed Engl 2005;44(19):2852-2869.
27. Uhlen M, Oksvold P, Fagerberg L et al. Towards a knowledge-based Human Protein Atlas. Nat Biotechnol 2010;28(12):1248-1250. doi: 10.1038/nbt 1210-1248.
28. Fuda NJ, Ardehali MB, Lis JT. Defining mechanisms that regulate RNA polymerase II transcription in vivo. Nature 2009;461(7261):186-192. doi: 10.1038/nature08449.
29. Sims RJ 3rd, Belotserkovskaya R, Reinberg D. Elongation by RNA polymerase II: the short and long of it. Genes De 2004;18(20):2437-2468.
30. Egloff S, Murphy S. Cracking the RNA polymerase II CTD code. Trends Genet 2008;24(6):280-288. doi: 10.1016/j.tig.2008.03.008.
31. Phatnani HP, Greenleaf AL. Phosphorylation and functions of the RNA polymerase II CTD. Genes Dev 2006;20(21):2922-2936.
32. Kohoutek J. P-TEFb - the final frontier. Cell Div 2009;4:19. doi: 10.1186/1747-1028-4-19.
33. Peterlin BM, Price DH. Controlling the elongation phase of transcription with P-TEFb. Mol Cell 2006;23(3):297-305.
34. Chao SH, Price DH. Flavopiridol inactivates P-TEFb and blocks most RNA polymerase II transcription in vivo. J Biol Chem 2001;276(34):31793-31799.
35. Wang Q, Young TM, Mathews MB et al. Developmental regulators containing the l-mfa domain interact with T cyclins and Tat and modulate transcription. J Mol Biol 2007;367(3):630-646.
36. Blazek D. The cyclin K/Cdk12 complex: an emerging new player in the maintenance of genome stability. Cell Cycle 2012;11(6):1049-1050. doi: 10.4161/cc11.6. 19678.
37. Bai X, Trowbridge JJ, Riley E, et al. TiFI-gamma plays an essential role in murine hematopoiesis and regulates transcriptional elongation of erythroid genes. Dev Biol 2013;373(2):422-430. doi: 10.1016/j.ydbio.2012. 10.008.
38. Emanuel PD. Juvenile myelomonocytic leukemia and chronic myelomonocytic leukemia. Leukemia 2008;22(7):1335-1342. doi: 10.1038/leu.2008.162.
39. Fort P, Rech J, Vie A et al. Regulation of c-fos gene expression in hamster fibroblasts: initiation and elongation of transcription and mRNA degradation. Nucleic Acids Res 1987;15(14):5657-5667.
40. Krumm A, Meulia T, Brunvand M et al. The block to transcriptional elongation within the human c-myc gene is determined In the promoter-proximal region. Genes Dev 1992;6(11):2201-2213.
41. Lin C, Smith ER, Takahashi H et al. AFF4, a component of the ELL/P-TEFb elongation complex and a shared subunit of MLL chimeras, can link transcription elongation to leukemia. Mol Cell 2010;37(3):429-437. doi: 10.1016/j. molcel.2010.01.026.
42. Mohan M, Lin C, Guest E et al. Licensed to elongate: a molecular mechanism for MLL-based leukaemogenesis. Nat Rev Cancer 2010;10(10):721-728. doi:10.1038/nrc2915.
43. Rougvie AE, Lis JT. The RNA polymerase II molecule at the 5'end of the uninduced hsp70 gene of D. melanogaster is transcriptionally engaged. Cell 1988;54(6):795-804.
44. Shilatifard A, Conaway RC, Conaway JW. The RNA polymerase II elongation complex. Annu Rev Biochem 2003;72:693-715.
45. Rahl PB, Lin CY, Seila AC et al. c-Myc regulates transcriptional pause release. Cell 2010;141(3):432-445. doi: 10.1016/j.cel1.2010.03.030.
46. Joshi PM, Sutor SL, Huntoon CJ et al. Ovarian cancer-associated mutations disable catalytic activity of CDK12, a kinase that promotes homologous recombination repair and resistance to dsplatin and poly (ADP-rlbose) polymerase Inhibitors. J Biol Chem 2014;289(13):9247-9253. doi: 10.1074/5bcM114.551143.
47. Zang ZJ, Ong CK, Cutcutache I et al. Genetic and structural variation in the gastric cancer kinome revealed through targeted deep sequencing. Cancer Res 2011;71(1):29-39. doi: 10.1158/0008-5472. CAN-10-1749.
48. Nissim-Rafinia M, Keřem B. Splicing regulation as a potential genetic modifier. Trends Genet 2002;18(3):123-127.
49. Ledermann J, Harter P, Gourley C et al. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol 2014;15(8):852-861. doi: 10.1 016/S1470-2045 (14) 70228-1.
50. Silver DP, Richardson AL, Eklund AC et al. Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer. J Clin Oncol 2010;28(7):1145-1153. doi: 10.1200/JC0.2009.22.4725.
51. Svoboda M, Slabý O, Foretová L. Molekulární genetika a individualizovaný přístup v onkoloii. In: Foretová L Svoboda M, Slabý O (eds). Molekulární genetika v onkologii. 1. vyd. Mladá fronta. In press 2014.